Elucid announced that it closed a Series B financing round with proceeds totaling $27 million.
Boston-based Elucid’s Series B round was led by an undisclosed strategic investor. A new investor, Biovision Ventures, participated, as did existing investors MedTex Ventures, IAG Capital, Bold Brain Ventures and BlueStone Venture Partners.
Elucid designed its FDA-cleared and CE-marked software platform to objectively quantify plaque morphology validated against tissue specimens, with algorithms developed through machine learning able to characterize tissue types in the artery wall known to cause heart attacks, such as lipid-rich necrotic core, according to a news release.
The platform’s capability to discern complex plaque biology at the cellular and molecular level powers new applications that can derive fractional flow reserve (FFRct), risk of heart attack/stroke, and expression prediction to inform therapeutic selection. Elucid said its approach…